Search Results

Business

Viatris, Idorsia Ink $350M R&D Pact for Two Phase III Assets

Under the research and development agreement announced Wednesday, Viatris is securing global rights to Idorsia’s late-stage heart and lupus candidates.

February 28, 2024

·

2 min read

·

Tyler Patchen

Business

Idorsia and Viatris enter into a significant global research and development collaboration

Idorsia Ltd announced that it has entered into agreements for a significant global research and development collaboration with Viatris Inc.

February 28, 2024

·

9 min read

Pictured: Idorsia's office in Switzerland/iStock,

FDA

Idorsia Wins FDA Approval in Hypertension Months After J&J Returned Rights to Drug

Months after Johnson & Johnson turned its back on the hypertension treatment Tryvio, Idorsia has secured the FDA’s nod for the endothelin receptor blocker.

March 21, 2024

·

2 min read

·

Tristan Manalac

Press Releases

Idorsia announces financial results for the first half 2024

July 25, 2024

·

26 min read

Business

Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration

Viatris Inc. and Idorsia Ltd announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.

February 28, 2024

·

16 min read

FDA

US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives

Idorsia Pharmaceuticals U.S. Inc. announced today that the US Food and Drug Administration (FDA) has approved TRYVIO™ (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs.

March 20, 2024

·

19 min read

Deals

Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company

Sosei Group Corporation announces that it has resolved, at a meeting of the Board of Directors held on 20 July 2023, to acquire from Idorsia Ltd and Idorsia Pharmaceutical Ltd all shares of Idorsia Pharmaceuticals Japan Ltd and Idorsia Pharmaceuticals Korea Co., Ltd .

July 20, 2023

·

17 min read

Pharm Country

Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS

Idorsia Ltd (SIX: IDIA) and Idorsia Pharmaceuticals US Inc. today announced that, effective immediately, CVS is covering QUVIVIQ® (daridorexant) CIV on the Performance Drug List (PDL).

July 10, 2023

·

9 min read

Pharm Country

Tausif (‘Tosh’) Butt to Join Idorsia Pharmaceuticals U.S. as President and General Manager

Idorsia Pharmaceuticals U.S. Inc. announced that Tausif Butt will join the organization as the new President and General Manager on September 5, 2023.

August 31, 2023

·

5 min read

Deals

Sosei Heptares - Investor and Press Conference on Today’s Announcement Regarding the Acquisition and License Transaction with Idorsia

Sosei Group Corporation, will hold an investor and press conference on ’s announcement; “Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC, Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company.”

July 20, 2023

·

3 min read